نتایج جستجو برای: carboplatin

تعداد نتایج: 5609  

2017
Yong Liu Chunxi He Xianping Huang

Platinum-based chemotherapeutic drugs are irreplaceable for the treatment of advanced non-small cell lung cancer (NSCLC). However, acquired drug resistance has become a major obstacle for the clinical application of chemotherapy on NSCLC. In the present study, we established carboplatin-resistant NSCLC models on A549 and PC9 cell lines, which were named A549/R and PC9/R. Besides the low sensiti...

Journal: :Journal of gynecologic oncology 2009
Sei-Jun Han Tae-Kyu Ahn Han-Song Choi Jin-Na Shin Sujan Piya Tae-Hyoung Kim

OBJECTIVE Platinum (Pt) based drugs including cisplatin and carboplatin are widely used as anticancer drugs in various human cancers. Many studies have shown that chemotherapeutic agents synergistically enhance cell death induced by death ligands. However it has been recently reported that cisplatin may inhibit tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced cell death t...

Journal: :Annals of oncology : official journal of the European Society for Medical Oncology 2012
R P Collea F W Kruter J E Cantrell T K George S Kruger A M Favret D L Lindquist A M Melnyk R E Pluenneke S H Shao M W Crockett L Asmar J O'Shaughnessy

BACKGROUND We determined the objective response rates produced by pegylated liposomal doxorubicin (PLD) plus carboplatin with/without trastuzumab (Herceptin). PATIENTS AND METHODS Patients with measurable disease were stratified by taxane treatment history and human epidermal growth factor receptor-2 status. TREATMENT PLD 30 mg/m(2) followed by carboplatin, day 1 of each 28-day cycle; human...

2011
Tanadech Dechaphunkul Kowit Pruegsanusak Duangjai Sangthawan Patrapim Sunpaweravong

BACKGROUND This study aimed to evaluate acute major toxicities, the response rate, 3-year overall survival and progression-free survival rate of locally advanced nasopharyngeal carcinoma patients on concurrent carboplatin chemoradiotherapy followed by carboplatin and 5-fluorouracil. METHODS A prospective study of fifty patients diagnosed with locally advanced nasopharyngeal carcinoma received...

2015
Jingxin Mo Paul K. Eggers Xianjue Chen Muhammad Rizwan Hussain Ahamed Thomas Becker Lee Yong Lim Colin L. Raston

Vesicles 107 ± 19 nm in diameter, based on the self-assembly of tetra-para-phosphonomethyl calix[4]- arene bearing n-hexyl moieties attached to the phenolic oxygen centres, are effective in binding carboplatin within the cavity of the macrocycle under shear induced within a dynamic thin film in a continuous flow vortex fluidic device. Post shearing the vesicles maintain similar diameters and re...

Journal: :Pharmacotherapy 2016
Justin Lawson Jeffrey M Switchenko Trevor McKibbin R Donald Harvey

BACKGROUND When using area under the concentration-time curve-based strategies for dosing carboplatin, accurate estimation of glomerular filtration rate is required for determining dose. Commonly, the Cockcroft-Gault equation is used, which is dependent on measurement of serum creatinine (SCr). Because analysis of SCr changed to an isotope dilution mass spectrometry (IDMS) standard, we sought t...

2015
Rachel Brightwell Kassondra Grzankowski John Kasznica Peter J. Frederick

•Treatment of sex-cord stromal tumors with carboplatin and taxane is both feasible and safe.•FOXL2 mutations account for approximately 50% of these tumors.•Carboplatin and taxane may afford a favorable outcome.

Journal: :Reactions Weekly 2021

Journal: :Annals of oncology : official journal of the European Society for Medical Oncology 2011
M E L van der Burg I A Boere P M J J Berns

Several studies in the past have tried to improve the prognosis of ovarian cancer by increasing the dose intensity of platinum. Only 2 out of 12 randomized studies showed survival benefit at the cost of significant long-term toxicity. Dose-dense induction therapy with combined weekly paclitaxel (at a dose of 90 mg/m(2)) and weekly carboplatin [at an area under the curve (AUC) of 4 mg·ml/min] fo...

Journal: :Indian Journal of Pharmaceutical Sciences 2022

We attempt to study the efficacy and adverse reactions of carboplatin, nab-paclitaxel regimen combined with atezolizumab in non-small cell lung cancer treatment. randomly selected 120 patients who received therapy our hospital from January 2019 December 2021 divided them into two groups, 60 cases respectively. Treated control group carboplatin paclitaxel pembrolizumab, while observation albumin...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید